Immune checkpoint inhibitors increase in the number of activated CD8 + T cells infiltrating into tumor tissues, thereby enhancing the antitumor effects. In addition, anti-CTLA-4 antibody therapy may be effective against regulatory T cells in the cancer immunosuppressive microenvironment. This is the rationale for the use of combination therapy with an anti-PD-1/PD-L1 antibody and an anti-CTLA-4 antibody, and several trials evaluating these combinations for the treatment of HCC are currently ongoing ( Table 2) . The CheckMate 040 study tested the efficacy of nivolumab in combination with ipilimumab at varying doses and dose intervals. Another trial comparing the efficacy and safety of combination therapy with durvalumab (anti-PD-L1 antibody) plus tremelimumab (anti-CTLA-4 antibody) to those of monotherapy is currently ongoing. The results of phase I of this phase I/II study were reported at the ASCO 2017 with favorable outcomes (ORR of 25.0% in 40 cases) [9] ; the eagerly awaited phase II is expected to be completed in April 2018.
Combination of Immune Checkpoint Inhibitors and Molecular Targeted Therapy
The therapeutic outcomes of nivolumab plus ipilimumab are superior to those of monotherapy in melanoma [6, 10] . Therapy involving an immune checkpoint inhibitor plus a molecular targeted agent was suggested as a promising strategy in recent years. In HCC, interstitial cells (Kupffer cells, dendritic cells, liver endothelial cells, and liver stellate cells) and immunosuppressive cytokines (e.g., IL-10 or TGF-β) may contribute to the immunosuppressive environment, and the PD-1/PD-L1 pathway plays an important role in the development of the immunosuppressive microenvironment in HCC. Combining a molecular targeted agent and an immune checkpoint inhibitor is expected to improve this immunosuppressive microenvironment [11] (Fig. 2) . Table 3 shows the currently ongoing trials evaluating combination therapy involving immune checkpoint inhibition with molecular targeted therapy. A trial evaluating the combination of pembrolizumab and lenvatinib for the treatment of HCC was started in Japan and then will be expanded to the rest of the world. High response rates (50-70%) and the longlasting durable response of this combination therapy in other types of solid cancer (e.g., kidney cancer and endometrial cancer) were presented at the ESMO 2016 and ASCO 2017. Therefore, similar high response rates and long-lasting durable responses are highly expected in HCC as well. The mechanism underlying the synergistic effect of an immune checkpoint inhibitor plus a molecular targeted agent, unlike that of the combination of two immune checkpoint inhibitors, needs to be thoroughly clarified. Regarding the mechanism of action of pembrolizumablenvatinib combination therapy [12] , a preclinical study including in vitro and in vivo studies showed that suppression of tumor-associated macrophages, regulatory T cells, and other constituents of the tumor-suppressive microenvironment resulted in decreases in TGF-β and IL-10, the downregulation of PD-1 and Tim3, and the upregulation of ICOS and OX40, thereby inducing tumor immunity through IL-12 [13] (Fig. 2) . It is anticipated that similar future studies on HCC will identify the best combination between a specific immune checkpoint inhibitor and molecular targeted agent. In addition to pembrolizumab-lenvatinib combination therapy (Fig. 3) , many similar combination therapies for HCC are currently being evaluated in early-phase clinical trials (Table 3) .
Combination of Immune Checkpoint Inhibitors with an Existing Locoregional Therapy
A different approach, namely, combining an immune checkpoint inhibitor with an existing locoregional therapy for HCC, is currently under evaluation. Transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA), or radiation therapy is expected to enhance the effects of immunotherapy by inducing local inflammation. This would lead to the release of neoantigens that activate antigen presentation and the relevant immune system activation. These locoregional therapies are particularly beneficial when the levels of cancer antigens are negligible because of poor antigen release. The results of combination therapy with an anti-CTLA-4 antibody and locoregional therapy in advanced HCC were recently published [14] . The NCT01853618 study evaluated the efficacy of adjuvant therapy with tremelimumab (anti-CTLA-4 antibody) after RFA or TACE in several, but not all, HCC nodules, with favorable outcomes, including a partial response rate of 26%, time to tumor progression of 7.4 months, and overall survival of 12.3 months. Increases in CD3 + and CD8 + cells in untreated nodules were clearly confirmed and attributed to the abscopal effect. Immune checkpoint inhibitors (antibodies to PD-1, PD-L1, and CTLA-4) are potentially beneficial in all forms of neoadjuvant therapy, adjuvant therapy after resection or ablation, and in combination with TACE, cytotoxic chemotherapy, or radiotherapy (Fig. 1) .
HCC recurrence rates after curative therapy (resection or ablation) are particularly high, and its management remains an unmet need. This is mainly because of the presence of Phase II, exploratory study, Japan extremely small microsatellite metastatic lesions that are undetectable by imaging even at the time of resection or ablation. To address this issue, various agents (e.g., IFN, peretinoin, vitamin K, and sorafenib) were tested for their efficacy as an adjuvant therapy in clinical trials, although all showed negative results [15] [16] [17] [18] . Theoretically, microsatellite lesions and intrahepatic metastases may be suppressed by administration of anti-PD-1 antibody after recruitment of cytotoxic T lymphocytes to the microsatellite lesions upon release of tumor antigens by TACE or RFA [19] . Mizukoshi et al. [20] observed a significant increase in tumor-specific T cells, which is indicative of posttreatment tumor antigen release, after RFA in 62% of patients, and a significant correlation between tumor-specific T cells and recurrence-free survival.
A clinical trial of nivolumab in the adjuvant setting after curative treatment was started in February 2017 in Japan (Fig. 4) . The combination strategy of an immune checkpoint inhibitor in the adjuvant setting with curative therapy (resection or RFA) is anticipated to prevent HCC recurrence effectively.
Conclusion
Padmanee Sharma and James P. Allison predicted the possibility of long-term survival and real cure in patients who responded to combination treatment with immune checkpoint inhibitors and molecular targeted agents because its high efficacy can lead to "cure in a real sense" [21, 22] (Fig. 5) . Indeed, immune checkpoint inhibitors will extend the overall survival of HCC patients, and, further, combination therapy with molecular targeted agents may result in real cure, which might lead to a paradigm shift in the treatment of HCC.
Emerging therapeutic strategies involving immune checkpoint inhibition combined with other treatment modalities will definitely change the future landscape of HCC treatment. 
